KYORIN, Flutiform Will Make its Japanese Debut Soon - A game changer for Kyorin!
Following the second PAFSC committee recommendation, Flutiform (Fluticasone propionate + formoterol) fixed dose combination is likely to get Japanese approval in September. It will be the third LABA + ICS entering Japanese market for the treatment of Asthma. In Global studies, Flutiform has demonstrated non-inferiority to Seretide Evohaler MDI (Chart 1) and Symbicort Trubohaler. Key advantage with Flutiform is its faster onset of action which gives rapid relief from wheeziness and waking to asthma patients compared to Seretide. We understand that Skyepharma Skyedry formulation technology designed for Flutiform pMDI (Pressurized metered dose inhaler), enhances the compliance and reduces the risk of overdosage, but it provides less dose flexibility compared to Symbicort Trubohaler. Flutiform is available in MDI device while Advair and Symbicort are available both in MDI/DPI
